PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths. The effect of the PI3K/PTEN/AKT/mTOR signaling pathway on cancer treatment, including NSCLC, has been well documented. In this study, we analyzed associations between genetic variations within this pathway and clinical outcomes following platinum-based chemotherapy in 168 patients with stage IIIB (wet) or stage IV NSCLC. Sixteen tagging SNPs in five core genes (PIK3CA, PTEN, AKT1, AKT2, and FRAP1) of this pathway and identified SNPs associated with development of toxicity and disease progression. We observed significantly increased toxicity for patients with PIK3CA:rs2699887 (OR: 3.86, 95% CI: 1.08-13.82). In contrast, a SNP in PTEN was associated with significantly reduced risk for chemotherapeutic toxicity (OR: 0.44, 95% CI: 0.20-0.95). We identified three SNPs in AKT1 resulting in significantly decreased risks of distant progression in patients carrying at least one variant allele with HRs of 0.66 (95% CI: 0.45-0.97), 0.52 (95% CI: 0.35-0.77), and 0.62 (95% CI: 0.42-0.91) for rs3803304, rs2498804, and rs1130214, respectively. Furthermore, these same variants conferred nearly 2-fold increased progression-free survival times. The current study provides evidence that genetic variations within the PI3K/PTEN/AKT/mTOR signaling pathway are associated with variation in clinical outcomes of NSCLC patients. With further validation, our findings may provide additional biomarkers for customized treatment of platinum-based chemotherapy for NSCLC.
Pu
Xia
X
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Hildebrandt
Michelle A T
MA
Lu
Charles
C
Lin
Jie
J
Stewart
David J
DJ
Ye
Yuanqing
Y
Gu
Jian
J
Spitz
Margaret R
MR
Wu
Xifeng
X
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D058534:Class I Phosphatidylinositol 3-Kinases; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D020641:Polymorphism, Single Nucleotide; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism
D016190:Carboplatin; D002945:Cisplatin; D058534:Class I Phosphatidylinositol 3-Kinases; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human; C484760:PIK3CA protein, human; C494918:AKT1 protein, human; C494921:AKT2 protein, human; C494929:PTEN protein, human
Oncogene. 2003 Oct 20;22(47):7265-79
14576837
Nat Genet. 1999 Jan;21(1):99-102
9916799
Nature. 2006 May 25;441(7092):424-30
16724053
Curr Treat Options Oncol. 2008 Dec;9(4-6):326-42
19225891
Cancer Res. 2007 Jul 1;67(13):6325-32
17616691
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cancer Res. 2006 Mar 15;66(6):3126-36
16540663
Apoptosis. 2008 Feb;13(2):259-71
18071906
J Clin Oncol. 2009 Feb 20;27(6):857-71
19164214
Oncogene. 1998 Jul 30;17(4):449-54
9696038
Nat Rev Cancer. 2005 Dec;5(12):921-9
16341083
Cell. 2007 Jun 29;129(7):1261-74
17604717
Semin Radiat Oncol. 2003 Jul;13(3):176-81
12903007
Oncogene. 1998 Jul 30;17(4):475-9
9696041
Cancer Treat Rev. 2007 Feb;33(1):9-23
17084534
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Clin Cancer Res. 2002 May;8(5):1178-84
12006535
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
16341064
Oncogene. 2008 Sep 18;27(41):5497-510
18794884
Ann N Y Acad Sci. 2007 Jan;1095:82-9
17404021
Hum Pathol. 2005 Jul;36(7):768-76
16084946
Int J Cancer. 2008 May 15;122(10):2380-4
18224693
Cancer Res. 2001 May 15;61(10):3986-97
11358816
ScientificWorldJournal. 2004 Aug 06;4:589-604
15349502
Oncogene. 1998 Sep 24;17(12):1557-65
9794233
Cell Signal. 2002 May;14(5):381-95
11882383
Mutat Res. 2001 Jul 1;478(1-2):23-43
11406167
N Engl J Med. 2004 Jan 22;350(4):379-92
14736930
Gynecol Oncol. 2005 Apr;97(1):26-34
15790433
J Clin Oncol. 2008 Oct 1;26(28):4617-25
18678835